CTRP3 Therapeutic Agent for Autoimmune Disease Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The physiological roles of Clq/TNF-related protein 3 (CTRP3) in vivo are not well understood, and its role in autoimmune diseases such as rheumatoid arthritis (RA) is unclear, necessitating a novel therapeutic approach for these conditions.
Innovation Solution
Administration of CTRP3 to autoimmune disease models, including rheumatoid arthritis and multiple sclerosis, using CTRP3 knockout mice to study its effects and potential as a treatment agent, demonstrating its ability to reduce the incidence and severity of autoimmune arthritis.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing treatments (antibodies and inhibitors against inflammatory cytokines) are used for rheumatoid arthritis, then treatment effectiveness is improved for most patients, but treatment becomes ineffective for some patients or during the course of treatment
Solution Approach 1:
The patent introduces CTRP3 as a novel therapeutic agent that acts as an intermediary substance to treat rheumatoid arthritis through a different mechanism than existing cytokine-targeted therapies. CTRP3 binds to C1q and modulates immune responses, providing an alternative pathway that bypasses the limitations of current treatments and achieves therapeutic effects in patients who do not respond to conventional therapies.
2Reliability
If CTRP3 is administered to treat autoimmune diseases, then the incidence and severity of autoimmune arthritis is reduced, but the physiological roles of CTRP3 in vivo were previously unclear
Solution Approach 1:
The patent performs preliminary actions by first identifying and characterizing CTRP3's therapeutic effects through knockout mouse models and in vitro experiments, demonstrating its ability to reduce autoimmune arthritis incidence and severity. This preliminary characterization of therapeutic efficacy precedes and guides further investigation into its precise physiological mechanisms, allowing the therapeutic application to advance while physiological understanding continues to develop.
Data Source
Figure 1A~1D
Figure 2A~2D
Figure 3A~3E
AI summary
Provided is an agent for the treatment of an autoimmune disease, the agent comprising CTRP3, and a method for the treatment of an autoimmune disease, the method comprising: administering an agent, which comprises CTRP3 for the treatment of an autoimmune disease, to a subject in need of a treatment of an autoimmune disease.